Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...

MSD's plan to reduce its headcount by around 6,000, first revealed a couple of weeks ago, looks like it will start at its headquarters in Rahway, New Jersey. Confirmation of that has come in the form ...

MSD is a company that is ‘serious about science.’ In 2024, its global research and development investment reached $17.9 ...

Merck & Co (MSD) has taken the first of two possible plunges in its ongoing collaboration with Evaxion, gaining the rights to a mystery infectious disease vaccine candidate. The US big pharma decided ...

MSD in the Philippines’ “Di Mo DeCERV!” campaign has been awarded Bronze in the Advocacy category at this year’s ICE Awards, ...

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...